Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb;10(2):675–684. doi: 10.21037/tlcr-20-754

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2021 Translational Lung Cancer Research. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

Kaplan-Meier estimates for OS in bone metastatic LADC patients according to KRAS mutational status and therapeutic modalities including BTx and RTx. (A) LADC patients with tumors harboring KRAS mutations had significantly shorter median OS than those with KRAS WT tumors (median OSs were 5.1 vs. 10.2 months, respectively; P=0.008). (B) Patients receiving BTx had significantly increased median OS (vs. BTx-naive patients; median OS were 10.1 vs. 4.3 months, respectively, P=0.007). (C) Similarly, median OS was also significantly increased in LADC patients receiving RTx compared to those who did not receive RTx (median OSs were 11 vs. 5.9 months, respectively P=0.021). BTx, bisphosphonate therapy; LADC, lung adenocarcinoma; OS, overall survival; RTx, radiation therapy; WT, wild-type.